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This review aimed to address the concept of adherence to adjuvant therapy in 
post-menopausal women. Thirteen studies were included in the review. Study 
quality was assessed using Critical Appraisal Skills Programme and CONSORT 
tools. Adherence to adjuvant medication was assessed using a variety of 
methods. Estimates of adherence rates to adjuvant therapies indicated that of the 
post-menopausal women prescribed adjuvant therapy, between 15% and 55% 
were adherent to tamoxifen from 1 to 5 years of follow-up, albeit two studies 
proposed adherence rates greater than 85%; these data may be flawed due to 
the methods of data collection. Between 31% and 73% of women were adherent 
to anastrozole, letrozole or exemestane from 1 year of treatment. These 
estimates of adherence are based on a variety of reported records including self-
report. Current evidence on the assessment of adherence to adjuvant therapies in 
post-menopausal women indicate that the adherence rates of medication maybe 
suboptimal and therefore therapeutic efficacy is questionable and may increase 
the risk of cancer recurrence and reduce disease survival rates. Concerted 
research is needed to investigate adherence rates, examine patient health beliefs 
in the medication management of postmenopausal breast cancer patients and 
also develop new measures to assess adherence with medication. 
 
Keywords: breast cancer, non-adherence, adjuvant therapy, oncology, side 
effects, medicines, post-menopause, older women. 
 
 
INTRODUCTION 
 
Medication-taking behaviour is an important concept particularly when the 
medication aims to support disease-free survival. This behaviour may be 
determined by the balance between the perceived benefits and risks the patient 
associates with the prescribed medication. When the risks outweigh the benefits, 
non-adherence with medicines can result. Two forms of non-adherence are noted: 
intentional non-adherence and non-intentional non-adherence (Banning 2008). 
Both forms can occur independently and jointly. In the intentional form, patients 
intentionally refuse to adhere to medicine regimens often due to lack of 
medication education, disinterest in treatment regime, discordant health beliefs 
and perceptions of illness encouraging failure to accept the need for treatment, 
complexity of the drug regimen, but also side effects and cost (Partridge et al. 
2003; Goldman et al. 2007) (Box 1). In the case of non-intentional non-
adherence forgetfulness, cognitive impairment polypharmacy and psychosocial 
issues are commonly cited causes (Banning 2008). Age, particularly older age, 
may have a negative impact on adherence with medication due to presence of co-
morbid conditions (Balkrishnan 1998). 
 
Various forms of adherence with medication are noted: adherers, partial 
adherers, erratic and over users, dropouts and partial dropouts (Partridge et al. 
2002). These different forms may relate to the dosing interval, drug regimen and 
perceived impact of treatment and benefit of prolonged therapy. 
 
Box 1. Factors associated with poor adherence with medication 
 
Complexity of medication regimen. 
 
Exposure to adverse effects of medicines. 
 
Deficient belief in value of prescribed medicines. 
 
Cognitive deficits and forgetfulness in relation to adhering to medication 
regimen and timing of medicine doses. 
 
Lack of awareness of therapeutic benefit of medicines. 
 
Poor relationship with prescriber & lack of education on importance of 
adherence patterns and possible risk reduction. 
 
Lack of awareness of possible adverse effects of medicines. 
 
Inadequate dialogue with prescriber on possible medication-related 
issues/concerns. 
 
Missed follow-up appointments. 
 
Inadequate follow-up. 
 
Feature and review paper 
Adherence rates with oral medication in oncology patients range from 20% to 
100% and may depend on cancer type, age of study participants, the definition of 
adherence used in studies and the variety of measuring tools employed. These 
features can prohibit the comparability of studies and their outcomes and 
influence the efficacy of interventions used to assess adherence (Partridge et al. 
2003; Ruddy et al. 2009). In post-menopausal women with oestrogen receptor 
(ER)-positive breast cancer, the ER modulator tamoxifen was, until recently, the 
most prescribed adjuvant endocrine therapy (Baum et al. 2002). Tamoxifen was 
recognised as a therapy that could reduce the risk of recurrence in the 
contralateral breast (Fisher et al. 1996; Jahanzeb 2007) and breast cancer 
mortality by up to 26% and maintain a post-treatment effect for up to 4 years 
[Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2005]. This is 
important as the risk of recurrence of breast cancer is increased in women in 2.5 
years of diagnosis (Kennecke et al. 2008). More recently, the third-generation 
aromatase inhibitors (AIs), anastrozole, exemestane and letrozole, have been 
shown to be superior to tamoxifen due to improved efficacy, rates of disease-free 
survival and incidence of contralateral breast cancer but also the delayed time to 
recurrence phase and quantity of metastases (Forbes et al. 2008; Ingle et al. 
2009). Moreover, the development of non-breast malignancy such as endometrial 
cancer is lower with letrozole and anastrozole compared to tamoxifen (Jakesz et 
al. 2005). Disease-free survival appears to be greater with letrozole and 
anastrozole (Cella et al. 2006), but total survival remains similar especially with 
exemestane compared to tamoxifen (Coombs et al. 2004). 
 
These AIs also possess a better safety profile than tamoxifen [Goss et al. 2005; 
Cella et al. 2006; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialist’s 
Group 2008]. Although AIs such as anastrozole and letrozole produce similar side 
effects to tamoxifen, these may differ due to mode of action. Third-generation AIs 
reduce endogenous oestrogen by blocking the conversion of androgens to 
oestrogen via the aromatase enzyme, whereas tamoxifen competitively inhibits 
oestrogen binding to ERs (Baum et al. 2002; Ponzone et al. 2008). 
 
The profile of side effects for both AIs and tamoxifen, albeit extensive, vary in 
intensity. Women administering adjuvant hormone therapy will experience hot 
flashes due to oestrogen deprivation but these may be less severe with AIs 
compared to tamoxifen (Coates et al. 2007). Oestrogen inhibition due to 
treatment with AIs and tamoxifen also increases osteoclastic activity, adversely 
influences bone remodelling and reduces bone density which can increase the risk 
of fractures particularly in the lumbar spine and hips. Reports indicate that the 
fracture risk is equivalent for both AIs and tamoxifen (Jakesz et al. 2005; 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialist’s Group 2008). In 
addition, AIs are reported to cause pain and stiffness in joints (Coates et al. 
2007). 
 
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) study and 
other studies indicated that AIs have a better profile than tamoxifen in terms of 
venous thromboembolic events (Jakesz et al. 2005). However, data on 
tamoxifen- and anastrozole-induced hypercholesterolaemia is conflicting with 
reported increments (Jakesz et al. 2005) and reductions in total cholesterol and 
lactate dehydrogenase (Tominaga et al. 2010). Moreover, oestrogen deprivation 
can increase menopausal symptoms such as alterations in weight, appetite, 
nausea, breast sensitivity, fluid retention, depression, vaginal discharge and 
bleeding, risk of endometrial cancer (Partridge et al. 2003; Fink et al. 2004). 
Perhaps, the more disturbing side effects are those involving genitourinary 
atrophy and its impact on sexual such as vaginal dryness and urinary function 
that can lead to a reduced quality of life in women (Winer et al. 2005). The 
plethora of side effects can possibly influence adherence with medication.  
 
 
A drawback of prescribing AIs is the deficient evidence on the long-term toxicity 
and the optimal treatment duration (Colozza et al. 2008). Although oncologists 
may preferentially prescribe AIs in older women with ER-positive breast cancers 
due to increased efficacy and tolerability (Wong et al. 2010), adherence with 
medication is a prominent issue not only for AIs but also for tamoxifen 
irrespective of reported benefits of therapy (Chlebowski & Geller 2006). There is 
no guarantee of cancer-free survival (Atkins & Fallowfield 2006).  
 
Current evidence on adherence with medication is limited (Chlebowski & Geller 
2006). A recent systematic review identified that non-adherence to AIs was 
equivalent to that of tamoxifen circa 20–23% and 30–50% in studies over 4 
years. The paucity of evidence in this area merits further investigation. 
 
METHODS 
 
This review aimed to provide a succinct account of the range of existing evidence 
that has explored and researched adherence with medication in postmenopausal 
women receiving adjuvant therapy for breast cancer. This review provides 
insights on the range of evidence pertinent to women’s ability to adhere to 
adjuvant therapy. 
 
Search strategy 
 
The search strategy involved the use of the following databases: Pubmed, 
Medline, Cochrane Library, PsychoInfo, British Nursing Index and the search 
engine Advanced Google Scholar. Evidence was also generated from hand 
searching individual journals. A defined search strategy was undertaken using the 
following terms: postmenopausal women, older women, breast cancer, early 
breast cancer, adjuvant therapy, tamoxifen, anastrozole, aromatase inhibitors, 
breast cancer patients, adherence and compliance. Search terms were used in 
combination. Research studies, exploratory studies, quantitative research 
designs, cohort studies and randomised controlled trial (RCT) were included in the 
review. To include an appraisal of adherence research studies, searches were 
restricted to papers written in English that addressed adherence with adjuvant 
medication in post-menopausal breast cancer patients. The search involved 
papers published between January 1999 and March 2011 as it was believed that 
most relevant studies would be found within this period. Evidence was drawn 
from international and UK literature in an attempt to illustrate the complexity and 
depth of the subject and the global nature of the subject matter. 
 
Selection criteria 
Using a combination of the above search terms, a total of 817 papers were 
identified electronically and by hand searching. Abstracts and titles were scanned 
for relevance. Papers that did not address adherence with adjuvant therapy in 
post-menopausal breast cancer patients were excluded. Also replicates identified 
by the search engine or database were excluded. RCTs of short duration less than 
3 months were also excluded as this short time scale would be insufficient to 
assess adherence to medication. Full-text papers not written in English were also 
excluded (Fig. 1). 
 
 
 
Figure 1. Diagram of search strategy. 
 
In total, 47 papers were selected for in-depth evaluation by initial reading and 
appraising the relevance and research design in relation to identified research 
outcomes. As this study focused on older women, preference was given to studies 
that included women aged 50 years and older; however, in four studies the age 
range was variable and included women younger than 50 years (Grunfeld et al. 
2005; Atkins & Fallowfield 2006; Partridge et al. 2008; Sedjo & Devine 2011). 
These studies were felt to be relevant and made a significant contribution to the 
study so were included. This decision was also supported by the paucity of studies 
in this area of research. 
 Studies were excluded if they failed to address how adherence was measured or 
did not clearly identify the age range of patients or accurately discuss the 
research design. Of these, 13 studies emerged that examined adherence with 
adjuvant medication in post-menopausal women and met the selection criteria. 
These included: one RCT, one qualitative study, seven surveys, one longitudinal 
study and three cohort studies. The details of individual studies are presented 
(Table 1). 
 
Data analysis 
 
In this review, the CONSORT scoring was used to analyse the quality and rigour 
of RCTs. Using this scoring system, RCTs were assessed for quality using the 25-
item checklist. The checklist provides an indication of the factors that were 
considered in terms of the trial design, sample size, research outcomes and 
limitations (CONSORT 2010) (Table 2). 
 
Papers were appraised using a version of the Critical Appraisal Skills Programme 
(CASP) (1998). Using this method, studies were excluded if they were judged to 
be insufficiently focused on medication adherence or did not focus specifically on 
post-menopausal women. The design of studies included in this exercise varied 
from qualitative study using an interpretive design, cohort, longitudinal studies 
and questionnaire and database surveys. As studies differed in their intervention, 
outcomes measured, time scale involved and results, no meta-synthesis was 
possible. For this reason, a narrative synthesis of the evidence was undertaken. 
This allowed a subjective analysis of the relative merits of papers specific to the 
aims of the review and to what extent these were addressed and their 
contribution to adherence research. Each paper consistently identified and 
discussed issues related to the measurement of and tools used to measure 
adherence and also provided data on adherence rates with discussion on factors 
that influenced adherence. From these salient aspects, three themes emerged. 
 
 
RESULTS 
 
Studies that reported on measures of non-adherence with adjuvant medication 
were heterogeneous in terms of their quality, duration, patient population, 
measurement of adherence, outcome measures employed and assessment of 
follow-up. The three emergent themes included the definitions and measurement 
of adherence, estimates of non-adherence and factors perceived to influence non-
adherence. 
 
Definitions and measurement of adherence 
 
Adherence was not defined in all papers. In this review, adherence to drug 
therapy was defined ‘as the extent to which a patient adheres to a recommended 
dosage and intake interval’ (Ziller et al. 2009, p. 432). Self-reported and 
prescription controlled adherence have been used previously as measures to 
assess adherence (Partridge et al. 2003, 2008; Ziller et al. 2009). Prescription 
controlled adherence is also referred to as the medication possession ratio. This is 
the quotient of actual daily doses purchased to the recommended number of days 
over a specified time period. The most acceptable value for quantity for number 
of days of filled prescriptions is 80% (Partridge et al. 2003; Ziller et al. 2009). 
Patients are considered to be non-adherent if the medication possession ratio is 
≤80 (Partridge et al. 2003). 
 
Measurement of adherence across studies was heterogeneous. Cited approaches 
included: patient records (Demissie et al. 2001; Fink et al. 2004; Güth et al. 
2008), evidence from refill prescriptions from medical claims databases (Partridge 
et al. 2003, 2008; Hershman et al. 2011; Sedjo & Devine 2011), medical records 
review (Lash et al. 2006), individual patient interviews (Fink et al. 2004; Atkins & 
Fallowfield 2006; Lash et al. 2006), self-report (Grunfeld et al. 2005; Lash et al. 
2006), computer-assisted telephone interviews (Demissie et al. 2001) and 
physician questionnaire (Lash et al. 2006). Alternative methods included: 
validated beliefs about medicine questionnaires (Grunfeld et al. 2005), 
prescription information from automated pharmacy records (Owusu et al. 2008; 
Hershman et al. 2011), questionnaire (Ziller et al. 2009), standardised 
psychological measure using the multidimensional health locus of control scale 
(Atkins & Fallowfield 2006), pharmacy record check (Ell et al. 2009; Ziller et al. 
2009) and a structured patient decision support intervention (Ell et al. 2009). 
 
Estimates of non-adherence 
 
The rates of non-adherence for women prescribed either tamoxifen or anastrozole 
reported in studies ranged from 10.8% to 85%. These include Atkins and 
Fallowfield (2006) (55%), Demissie et al. (2001) (15%), Fink et al. (2004) 
(17%), Ell et al. (2009) (41%), Hershman et al. (2011) (28%), Lash et al. (2006) 
(31%), Güth et al. (2008) (10.8%), Owusu et al. (2008) (49%), Partridge et al. 
(2003) (21–32% at year 1, 32–50% by year 3), Sedjo and Devine (2011) (20.1% 
anastrozole, 25.3% letrozole, 30.6% exemestane and 37% tamoxifen) and Ziller 
et al. (2009) (20% tamoxifen and 31% anastrozole). The variation in these 
figures may be a reflection of the methods used to measure adherence. For 
example, reports on adherence to tamoxifen indicate that rates of non-adherence 
were most prevalent in non-Caucasian women (OR 1.62, 95% CI 1.26–2.09), 
women aged 75 to 84 years (OR 2.61, 95% CI 1.30–5.23) and in mastectomy 
patients (OR 1.64, 95% CI 1.33–2.02) (Partridge et al. 2003). 
 
Partridge et al.’s adherence rates cited in 2003 in older women and mastectomy 
patients concur with more recent studies (Owusu et al. 2008). Findings indicate 
that 49% of women with ER-positive breast cancer are more likely to be non-
adherent with medication. Of these, 20% were in the 75 to 80 age group 
[hazards ratio (HR) 2.02, 95% CI 1.53–2.66] or patients with a history of 
mastectomy (HR 1.62, 95% CI 1.18–2.22) (Owusu et al. 2008). Older women 
aged 75+ years also featured as a significant group that can be non-adherent 
with tamoxifen (Demissie et al. 2001; Partridge et al. 2003; Lash et al. 2006). 
 
Adjuvant therapy is normally prescribed for 5 years. Two studies reported high 
rates of non-adherence with anastrozole in 4 years of therapy (Grunfeld et al. 
2005, 46%; Partridge et al. 2008, 32–50%). More recently, Ziller et al. (2009) 
reported non-adherence rates for tamoxifen of 20% and anastrazole of 31% 
between 1 and 4 years of therapy. The rates for anastrozole concur with those of 
Partridge et al. (2008). 
 
A recent questionnaire survey found that 46% of women reported non-adherence 
within 2 years of therapy (Grunfeld et al. 2005). This concurs with previous 
reports that by 4 years of treatment, non-adherence rates were as high as 50%. 
More recent reports indicate that mean adherence decreased each year from 78% 
in year 1 to 66–50% by year 3 (Partridge et al. 2008). These data concur with 
the percentage reduction in adherence rates (17%) identified after the first and 
second years of therapy (Fink et al. 2004) and also an annual 10% reduction in 
adherence rate (Güth et al. 2008; Owusu et al. 2008). Reasons attributed to the 
annual reduction in rates include: side effects, the extension of menopausal 
symptoms, fear of adverse effects and the development of non-breast cancer 
second tumours (Demissie et al. 2001; Grunfeld et al. 2005). Relevant incidence 
data for the discontinuation of tamoxifen therapy due to development of side 
effects (HR per side effect 1.2, 95% CI 0.97–1.5) were: quantity of existing 
medications (HR 0.90, 95% CI 0.81–0.99) and addition of new medications (HR 
1.2, 95% CI 1.0–1.4) (Lash et al. 2006). 
 
Factors influencing non-adherence 
 
Alternative contributing factors to non-adherence with medication included a lack 
of interest and a dislike of taking medicines. In such cases, younger women and 
those aged under 57.6 years were intentionally non-adherent with their 
medication, often refusing to adhere to treatment regimens. This concurs with 
published data (Partridge et al. 2003; Atkins & Fallowfield 2006). The occasional 
and intermittent skipping of drug doses was often related to lower health scores, 
implied reduced locus of control in relation to health concerns (Atkins & 
Fallowfield 2006). Women also perceived a lack of benefit from medicines which 
outweighed the risks associated with treatment (20% of women), forgetfulness 
(18% of women) (Grunfeld et al. 2005) but also negative health beliefs about the 
value and importance of therapy (3.0, 95% CI 1.6–5.6) (Fink et al. 2004). Non-
adherence with medication was also common in women with up to four positive 
lymph nodes (OR 2.5, 95% CI 1.0–6.3) (Fink et al. 2004). In this study, the 
characteristics of women differed from most cited studies; women were 
predominantly Caucasian, well educated, mean age of 60 years, three to four co-
morbidities and negative health beliefs. These factors may have had an impact on 
non-adherence data. Sedjo and Devine (2011) also reported a higher rate of non-
adherence in women with secondary breast cancer and existing co-morbidities 
such as depression, heart disease and diabetes but also in younger women. 
 
Only one study acknowledged the form of non-adherence experienced by patients 
(Atkins & Fallowfield 2006). The mean age of non-adherent women was 59.4 ± 
11.534 years. Non-adherence with tamoxifen was identified in 55% of patients. 
Of these, 15% were intentionally non-adherent and 85% non-intentionally non-
adherent. By comparison of the patients prescribed anastrozole, 61% were non-
adherent with medication. Of these, 18% of patients were intentionally non-
adherent and 82% non-intentionally non-adherent. In summary, 83% of the non-
intentional non-adherers forgot to take their medication compared to 17% of the 
intentional non-adherers who chose not to administer their prescribed medication 
(Atkins & Fallowfield 2006). 
 
DISCUSSION 
 
In the studies examined, the ability of post-menopausal breast cancer patients to 
adhere to adjuvant therapy varied. Adherence rates for tamoxifen varied from 
15% to 85% (50–77%) [Demissie et al. 2001 (83%); Partridge et al. 2003, 2008 
(50%–85%); Fink et al. 2004 (83%); Grunfeld et al. 2005; Atkins & Fallowfield 
2006 (45%); Lash et al. 2006 (69%); Owusu et al. 2008 (51%); Hershman et al. 
2011 (39.2%); Sedjo & Devine 2011 (63%); Ziller et al. 2009 (80%)]. 
 
Rates for anastrozole ranged from 27.7% to 81% [Atkins & Fallowfield 2006 
(39%); Partridge et al. 2008 (72–81%); Ziller et al. 2009 (69%); Hershman et 
al. 2011 (27.7%); Sedjo & Devine 2011 (69.4–79.3% for AIs)]. The data for 
tamoxifen concur with reported estimates identified in clinical trials of less than 4-
year duration; however, the adherence rate estimate for anastrozole varies from 
published accounts (Chlebowski & Geller 2006). In trials and studies of 4 years 
and longer, non-adherence rates with tamoxifen increased to 30–50% (Hershman 
et al. 2011). These data concur with published studies (Partridge et al. 2003). 
What is unclear is whether clinical trial data also pertain to specific categories of 
older women, for example, those aged 75 years and older. The difference in 
adherence rates for tamoxifen and anastrozole may be due to the onset of, and 
severity of, drug-related side effects. Cella et al. (2006) found that women 
treated with anastrozole reported less dizziness and vaginal discharge compared 
to tamoxifentreated groups of women. 
 
In this review, the annual percentage reduction in adherence ranged from 10% to 
23% [Partridge et al. 2003, 2008; Fink et al. 2004 (10.8%); Owusu et al. 2008; 
Güth et al. 2008 (10%); Sedjo & Devine 2011]. This range is particularly high 
and the validity of the results may be subjected to potential flaws, especially the 
deficient detail on how adherence was measured and the relative accuracy of 
measurement. Studies in this review can be differentiated on the basis of their 
measurement of adherence and their accompanying validity, particularly those 
studies that employed self-assessment measures such as patient recall, medical 
records, pharmacy records, telephone interviews, retrospective documentary 
analysis, prescriber recall assessment but also patient interviews (Demissie et al. 
2001; Partridge et al. 2003, 2008; Fink et al. 2004; Grunfeld et al. 2005; Atkins 
& Fallowfield 2006; Lash et al. 2006; Güth et al. 2008; Ziller et al. 2009). Ziller et 
al.’s retrospective study employed a self-assessment measure in the form of a 
questionnaire to measure non-adherence supported by medical records and 
prescriber recall assessment. Findings indicate incongruence between what 
patients recall as 100% adherence and prescription refill records of 80% of 
patients on tamoxifen and 69% on anastrozole (Ziller et al. 2009). Limitations of 
using patient and prescriber recall as data collection tools is the subjective nature 
of the process with a tendency to over-estimate adherence; increased possibility 
of the ‘Hawthorne effect’ on outcome of data collected, subjective memory lapse 
and the veracity of responses may endorse data inaccuracies as participants may 
have no desire to acknowledge non-adherence due to choice (Horne & Weinman 
1999). Measuring medication adherence is restricted due to the lack of gold 
standard measurement tool (Banning 2009). Novel approaches to measuring 
adherence with medication are needed.  
 
Given the support for use of AIs anastrozole, letrozole and exemestane to treat 
early-stage breast cancer in postmenopausal women (Jakesz et al. 2005; Coates 
et al. 2007; Carpenter 2008; Colozza et al. 2008), more attention is needed to 
address adherence with medication in this group of patients. Although oncologists 
may recognise that adherence and patient persistence with medication is a 
problem, patient assessment in these issues is ad hoc (Davidson et al. 2007). 
 
Current adherence research acknowledges that communication is an important 
aspect of the prescriber/patient consultation (Silliman et al. 2002). Improvements 
can be made on patient medication management, discussion of the long-term 
benefits of medicines, recognition of, and discussion on, drug-induced side 
effects, both current and additional medicines and impact of patient lifestyle on 
efficacy of medicines (De Jong et al. 2008). Also worthy of consideration is the 
acknowledgement of patient’s health beliefs; the impact of a dislike of taking 
medicines particularly in younger women, and locus of control and their impact on 
medication-related decision making are important attributes of medication 
adherence (Siminoff & Fetting 1991; Braddock et al. 1997). These issues are 
especially important in intentionally non-adherent patients where perceptions of 
having less influence over health decisions and an underpinning lower internal 
locus of control may foster non-adherent behaviour (Horne & Weinman 1999). 
Patients with positive views about medication are more likely to continue with 
their therapy (Lash et al. 2006; Ruddy et al. 2009; Hadji 2010). This requires a 
good rapport between the patient and the prescriber supported by continuous 
follow-up procedures (Fink et al. 2004). 
 
 
Box 2. Measures to improve adherence 
 
Promote better interaction and dialogue with breast cancer patients through 
openness and communication. 
 
Encourage the development of a therapeutic alliance with breast cancer patients 
in order to promote improved communication. 
 
Enhance collaborative decision making by providing patients with choices 
regarding drug therapies available to them. 
 
Provide breast cancer patient with informed medication management education 
on the risks and benefits of prescribed medicines but also the importance of 
adhering to regimens. 
 
Provide regular follow-up appointments that are at a time that suit patients. 
 
 
 
Additional measures that can be implemented to improve adherence with 
medication include: improving medication education with specific reference to 
medication-related side effects, and their recognition (Davidson et al. 2007; Body 
2010) (Box 2). The development of side effects is an indication of adherence. It is 
also important to discuss the benefits associated with tamoxifen therapy, for 
example, protection against fractures involving weight-bearing joints which 
should be supported by dietary advice and possible supplementation with calcium, 
vitamin D and bisphosphonates (Gail et al. 1999; Hadji 2010). Also it is important 
to consider the potential risks of increased risk of deep venous thrombosis, 
pulmonary embolism, endometrial cancer as these conditions increase with age 
(Gail et al. 1999). Patient education to improve adherence is an important aspect 
of treatment and an area of ongoing research.  
 
Patients should be involved in conversations on treatment and in shared decision 
making in relation to the selection of medicines. This will enhance adherence 
through informed decision making the acknowledgement of treatment preference 
and selection of medicines from an informed stance. There is also a need to 
consider the psychological adjustments that women have to make. Women may 
have successfully completed chemotherapy and surgery but are reminded on a 
daily basis that the risk of recurrence requires them to administer medication 
even though they may feel healthy (Atkins & Fallowfield 2006). In this instance, 
counselling can be offered as appropriate (Body 2010). 
 
Adherence with medication can also be adversely influenced by financial 
commitments. In the USA, the cost of medicines is a key concern with many 
women having difficulties purchasing their medicines (Goldman et al. 2007). 
Limitations of this review are noted. It is important to note that when researching 
adherence with medication, one needs to consider that in clinical trial data 
reported rates of adherence may be higher than those reported in clinical settings 
and contribute to therapeutic failure (Hadji 2010). The studies included in the 
review employed a variety of research designs; the cohort study approach was 
the most common design used and time scales varied from 1 to 5 years. The 
shorter time scales (1–2 years) may provide an inaccurate picture of adherence 
history. Data collection approaches differed, and included questionnaire, medical 
records and self-report measures. The efficiency of these data collection 
approaches have drawbacks of poor response rates, retrospective and possibly 
incomplete accounts of records, and possible overestimations of adherence rates. 
Only Lash et al. (2006) attempted to triangulate the results using both 
questionnaire and interview approaches to authenticate the data. Although there 
is no gold standard approach to measure adherence, studies should employ a 
combination of data collection measures to provide an accurate assessment of 
adherence patterns.  
 
In addition, there is also a need to examine the impact of social factors that may 
adversely influence adherence such as the time required by medical professionals 
to adequately explain important drug regimens to women, the significance of the 
use of language during consultations and the impact of poverty, time 
management and social pressures and how they influence adherence with 
medication (Davidson et al. 2007). 
 
It is also important to review the profile of women most likely to not adhere to 
adjuvant therapy. Research to date suggests that older women can be segmented 
in relation to adherence patterns. Women with poorer adherence rates tend to be 
aged 55–64 years and >75 years with ER-positive breast cancer (Demissie et al. 
2001; Partridge et al. 2003; Fink et al. 2004; Güth et al. 2008). Even though 
women aged 75+ years are more likely to have good emotional health, may 
report less drug-related side effects and may engage with physicians to discuss 
drugs and drug-related effects, they are equally likely to be non-adherent with 
medication (Demissie et al. 2001). Profiling of women is difficult due to the 
deficiencies in measuring adherence and the absence of models to explain 
adherence (Fink et al. 2004). 
 
CONCLUSION 
From a global perspective, breast cancer is the most common cancer in post-
menopausal women and requires continuous treatment. A key message from this 
review is that the administration of adjuvant therapies in postmenopausal women 
is suboptimal. The reasons why some women fail to adhere to their hormonal 
medication is unclear. There is a paucity of research on the incidence and 
patterns of non-adherence with long-term adjuvant therapy in post-menopausal 
women (Hadji 2010). This area of research requires more concerted action to 
identify current trends in non-adherence with adjuvant therapies, to clarify 
patient health beliefs, perceptions of illness and support strategies needed, but 
also to increase disease-free survival of post-menopausal breast cancer patients 
through the promotion and maximisation of the benefits to be gained from 
adherence with adjuvant therapy. 
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Table 1. Published studies of adherence to oral adjuvant therapies in post-menopausal women with early/advanced-stage breast cancer 
 
 
AI, third-generation aromatase inhibitors (anastrozole, letrozole, exemestane); QoL, quality of life; RCT, randomised controlled trial. 
Table 2: Checklist of information to include when reporting randomised trials and surveys 
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